With the rise of biologics, cold chain has become ever more important in pharmaceuticals. Grey market diversion is also a perennial issue. Here we discuss how a supply chain network solution can address both of these and we calculate the value that can be achieved.
Pharmaceutical
End-to-end pharmaceutical development and supply chain, including clinical trials, raw materials, APIs, contract manufacturers, brands, distribution, retail, regulations, marketing, etc.
Quantifying the Value of Blockchain-Based Supply Chain Networks—Part Five
Pharmaceutical manufacturers can realize value by carefully and methodically reducing inventory, reducing the amount of drugs that expire, and reducing counterfeits in their supply chain, all by using a supply chain network solution. Here we describe the mechanisms and estimate the value of those improvements.
Quantifying the Value of Blockchain-Based Supply Chain Networks—Part Four
We estimate the value that a multi-enterprise supply chain network could potentially provide via patient adherence and ease of doing business improvements. The value is quantified for a hypothetical archetypal pharmaceutical manufacturer. We elucidate the key metrics improved, mechanisms of improvement, and typical improvement range expected.
Quantifying the Value of Blockchain-Based Supply Chain Networks—Part Three
We propose and specify a hypothetical multi-enterprise supply chain application network with functionality for track and trace/recall, cold chain, inventory management, patient adherence, and identity management. Then we estimate the potential value of using such a network for an archetypal pharmaceutical manufacturer.
Quantifying the Value of Blockchain-Based Supply Chain Networks—Part Two
Pharmaceutical supply chains face a number of challenges that could be mitigated by the adoption of multi-enterprise supply chain application network technology. Here we describe the structure of pharmaceutical supply chains and key challenges faced, such as: diverse and divergent incentives among different supply chain participants, complexity and opacity of product and financial flows, strict regulations, perishable products, and elusive patient adherence.
The Coming Wave of Pharma Supply Chain Regulations: Insights from TraceLink NEXUS ’15
New regulations across the globe are coming into effect, requiring pharmaceutical manufacturers, distributors, dispensers, and others up and down the chain to build serialization, verification, and traceability into the supply chain. At TraceLink’s NEXUS ’15 conference, we learned a lot about the impact of these new requirements, how companies are responding, and whether there is an ROI beyond compliance.
Supply Chain Risk Now?
The supply chain business community now includes Risk Management as a business priority and cites it as a key area in need of improvement. Are solution providers ready?
How the Pharmaceutical Industry Has Dramatically Reduced Thefts
The theft of pharmaceuticals has gone down dramatically in the past few years. Learn how they made such strides.
RFID in Pharmaceuticals
The discussion has moved from if to how for many major pharmaceutical manufacturers. The barriers to adoption are down and the benefits are up. So you may have a good reason to look at solutions now.
Carton-level Temperature Tracking for Cold Chain Pharmaceuticals – Why Now?
A look at the key role that carton-level RFID temperature tagging can have within today’s pharmaceutical cold chains.
Smart and Serialized
Architecting Serialization and Cold Chains for Food and Pharma.